Needham analyst Joseph Stringer maintained a Buy rating on Alnylam Pharma today and set a price target of $478.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Stringer has given his Buy rating due to a combination of factors including Alnylam Pharma’s impressive financial performance in the second quarter of 2025. The company reported a significant increase in total product revenue, surpassing both the firm’s and market expectations. This growth was primarily driven by the successful launch of Amvuttra for ATTR-CM, which has seen strong demand since its label expansion.
Additionally, the company’s revenue guidance for 2025 has been substantially raised, reflecting confidence in the continued success of its TTR franchise. The analyst also anticipates sustainable non-GAAP profitability starting in 2025, further supporting the positive outlook. As a result of these factors, the price target for Alnylam Pharma has been increased to $478, reinforcing the Buy recommendation.
According to TipRanks, Stringer is a 4-star analyst with an average return of 5.8% and a 42.05% success rate. Stringer covers the Healthcare sector, focusing on stocks such as Cidara Therapeutics, Alnylam Pharma, and Gilead Sciences.